Preparation and Characterization of a Novel Nanobody Against T-Cell Immunoglobulin and Mucin-3 (Tim-3) Publisher

Summary: Study develops anti-TIM-3 nanobody that suppresses leukemia cell growth, showing potential for immune-based cancer therapies. #CancerResearch #Nanobody

Homayouni V¹ ; Ganjalikhanihakemi M¹ ; Rezaei A¹ ; Khanahmad H² ; Behdani M³ ; Lomedasht FK³
Source: Iranian Journal of Basic Medical Sciences Published:2016

Abstract

Objective(s): As T-cell immunoglobulin and mucin domain 3 (TIM-3) is an immune regulatory molecule; its blocking or stimulating could alter the pattern of immune response towards a desired condition. Based on the unique features of nanobodies, we aimed to construct an anti-TIM-3 nanobody as an appropriate tool for manipulating immune responses for future therapeutic purposes. Materials and Methods: We immunized a camel with TIM-3 antigen and then, synthesized a VHH phagemid library from its B cell’s transcriptome using nested PCR. Library selection against TIM-3antigen was performed in three rounds of panning. Using phage-ELISA, the most reactive colonies were selected for sub-cloning in soluble protein expression vectors. The Nanobody was purified and confirmed with a nickel-nitrilotriacetic acid (Ni-NTA) column, SDS-PAGE and Western blotting. A flowcytometric analysis was performed to analyze the binding and biologic activities of theTIM-3 specific nanobody with TIM-3 expressing HL-60 and HEK cell lines. Results: Specific 15kD band representing for nanobody was observed on the gel and confirmed with Western blotting. The nanobody showed significant specific immune-reactivity against TIM-3 with a relatively high binding affinity. The nanobody significantly suppressed the proliferation of TIM-3 expressing HL-60 cell line. Conclusion: Finally, we successfully prepared a functional anti-humanTIM-3 specific nanobody with a high affinity and an anti-proliferative activity on an AML cell line in vitro. © 2016, Mashhad University of Medical Sciences. All rights reserved.